Hilton Worldwide Holdings just dropped its Q3 2026 scorecard and the stock slipped about 2% the next trading day, even though the hotel group posted adjusted EBITDA of roughly US$1.06b and adjusted earnings per share of US$2.45. On the surface that looks like a cooldown after a strong run, yet the business printed record organic hotel openings and a pipeline that continues to swell.
What you are seeing in that one day move is a sentiment check. Traders focused on a rich P/E and leverage flags, while the actual operating engine, rooms growth and revenue per available room momentum presented a more balanced story.
Like the rooms pipeline but uneasy about the rich P/E and leverage concerns around Hilton Worldwide Holdings? Consider balancing that mix by using our screener of companies that pair growth with stronger balance sheets in the list of solid balance sheet and fundamentals stocks (24 results) .
Q3 2026 Earnings Summary
-
Revenue (Q3 2026 vs. Q3 2025):US$3,325m vs. US$1,283m (very large increase, reflecting a step up in reported top-line scale).
-
Net Income, excl. extra items (Q3 2026 vs. Q3 2025):US$536m vs. US$420m (up about 27.6%).
-
Basic EPS (Q3 2026 vs. Q3 2025):US$2.39 vs. US$1.79 (up about 33.4%).
-
Net Margin, excl. extra items (Q3 2026 vs. Q3 2025):about 16.1% vs. about 32.7% (margin roughly halved year on year, indicating lower profitability per dollar of revenue).
Earnings only tell part of the story, because cash flows are what many valuation focused investors ultimately track when they judge whether a business is punchy or fair.
Looking through Hilton Worldwide Holdings' cash generation alone, the stock could be a whopping 39% overvalued .
Hilton pipeline ambition meets early execution tests
The bullish story hinges on Hilton turning a huge project list into fee rich hotels that actually open and perform.
"The main thing that has to go right is that Hilton converts its record 541,000 room pipeline, including a high share of lifestyle, extended stay, and collegiate brands, into profitable openings while owner-focused fee reductions and programs like RISE maintain or improve hotel-level margins."
Q3 delivered record organic openings above 27,000 rooms, 6% net unit growth and 37% of additions from conversions, which lines up with that ambition. RevPAR rose 5.8% and adjusted EBITDA reached US$1.06b, suggesting new keys are contributing, although the net margin contraction flags that owner margin uplift is not yet clearly visible.
RevPAR and renovation risks still show up in Hilton
The bear story argues that weak regions and renovations could quietly eat into Hilton's fee engine.
"Execution risk around property closures and heavy renovations at major owned hotels such as Munich Park, Amsterdam and Tokyo, which are currently creating an estimated US$20m to US$25m drag on annual EBITDA, could persist longer than planned or fail to yield sufficient fee and profit contribution after reopening, which would pressure segment earnings and overall profitability."
Current results still carry that renovation drag, and regional RevPAR softness is real, with China down 5.4% and Middle East and Africa RevPAR expected to decline by a low double digit rate for 2026. The 2.1 percentage point fall in net margin versus last year confirms that conversion and pipeline wins are not fully offsetting these pressures yet.
Not everyone reads the same price the same way. → See the higher figure this Narrative lands on, and how it gets there .
Hunt Mispriced Earnings Stories
Hilton Worldwide Holdings recently reported results that combined strong development activity with varied profitability metrics. The real opportunity is researching stocks that could be undervalued before the market reassesses their earnings power.
-
Company 1 - 19% below our estimate - targets rapid expansion of franchise and company teahouses while protecting unit economics through a shared supply chain and digital tools.
-
Company 2 - 22% below our estimate - ties together cloud services, productivity software and AI assistants so enterprise customers consolidate workloads onto one integrated ecosystem.
-
Company 3 - 26% below our estimate - scales production of injectable therapies for weight management and diabetes that prescribing doctors already use as front-line treatments.
Those are three of them. See all 29 potentially undervalued companies →
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include HLT .
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
